Try it
ENT · Vestibular disorders: betahistine mechanism
Sample itemBetahistine is prescribed to reduce the frequency of attacks in Meniere disease. What is its main pharmacological action?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
C. Weak H1 agonist and H3 antagonist
Betahistine is a histamine analogue acting as a weak H1 agonist and H3 antagonist, which is thought to improve labyrinthine microcirculation and vestibular compensation. H1 blockers such as dimenhydrinate, calcium channel blockers such as cinnarizine and muscarinic blockers such as hyoscine act as vestibular suppressants instead.
Option by option
A. Calcium channel blocker
Calcium channel blockade is the mechanism of cinnarizine and flunarizine.
B. Muscarinic antagonist
Muscarinic blockade is the mechanism of hyoscine used in motion sickness.
C. Weak H1 agonist and H3 antagonist (correct)
Correct. Betahistine is a weak H1 agonist and H3 antagonist, not a suppressant.
D. H1 receptor antagonist
H1 antagonism is the action of dimenhydrinate and similar vestibular suppressants.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More ENT questions
- AudiologyIn a tuning fork test, Rinne is negative (bone conduction louder than air conduction) in…
- EarWhich type of chronic suppurative otitis media is considered 'unsafe'?
- LarynxIn singers, vocal nodules typically occur at:
- Vestibular disordersA patient has recurrent attacks of vertigo lasting hours, with fluctuating low-frequency…